ATRST1
MCID: ATR087
MIFTS: 76

Atrial Standstill 1 (ATRST1)

Categories: Cardiovascular diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Atrial Standstill 1

MalaCards integrated aliases for Atrial Standstill 1:

Name: Atrial Standstill 1 57 74 29 6
Cardiomyopathy 63 40 17 33
Heart Block 44 63 72
Cardiomyopathy, Familial, with Conduction Disturbance 57 72
Atrial Cardiomyopathy with Heart Block 57 74
Cardiomyopathies 44 72
Atrst1 57 74
Familial Cardiomyopathy with Conduction Disturbance 74
Atrial Standstill, Digenic 57
Standstill, Atrial, Type 1 40

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
atrial standstill 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 108770
UMLS 72 C0018794 C0878544 C1838539

Summaries for Atrial Standstill 1

PubMed Health : 63 About cardiomyopathy: Cardiomyopathy (KAR-de-o-mi-OP-ah-thee) refers to diseases of the heart muscle. These diseases have many causes, signs and symptoms, and treatments. In cardiomyopathy, the heart muscle becomes enlarged, thick, or rigid. In rare cases, the muscle tissue in the heart is replaced with scar tissue. As cardiomyopathy worsens, the heart becomes weaker. It's less able to pump blood through the body and maintain a normal electrical rhythm. This can lead to heart failure or irregular heartbeats called arrhythmias (ah-RITH-me-ahs). In turn, heart failure can cause fluid to build up in the lungs, ankles, feet, legs, or abdomen. The weakening of the heart also can cause other complications, such as heart valve problems.

MalaCards based summary : Atrial Standstill 1, also known as cardiomyopathy, is related to progressive familial heart block and cardiomyopathy, dilated, 1e, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Atrial Standstill 1 is GJA5 (Gap Junction Protein Alpha 5), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Cardiac conduction. The drugs Verapamil and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and bone, and related phenotypes are first degree atrioventricular block and endocardial fibroelastosis

OMIM : 57 Atrial standstill (AS) is a rare condition characterized by the absence of electrical and mechanical activity in the atria. On surface ECG, AS is distinguished by bradycardia, junctional (usually narrow complex) escape rhythm, and absence of the P wave. Nearly 50% of patients with AS experience syncope. AS can be persistent or transient, and diffuse or partial (summary by Fazelifar et al., 2005). (108770)

UniProtKB/Swiss-Prot : 74 Atrial standstill 1: A rare arrhythmia characterized by the absence of electrical and mechanical activity in the atria. Electrocardiographically, it is characterized by bradycardia, the absence of P waves, and a junctional narrow complex escape rhythm.

Related Diseases for Atrial Standstill 1

Diseases in the Atrial Standstill family:

Atrial Standstill 1 Atrial Standstill 2

Diseases related to Atrial Standstill 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2095)
# Related Disease Score Top Affiliating Genes
1 progressive familial heart block 35.7 TNNT2 GJA5 DSP
2 cardiomyopathy, dilated, 1e 35.4 TTN MYH7 LMNA DSP
3 cardiomyopathy, dilated, 3b 35.1 TAZ DMD
4 restrictive cardiomyopathy 35.1 TTR TTN TNNT2 TNNI3 MYH7 MYBPC3
5 cardiomyopathy, familial hypertrophic, 6 35.0 TNNI3 PRKAG2
6 arrhythmogenic right ventricular cardiomyopathy 34.8 TTN RYR2 PRKAG2 PLN PKP2 MYH7
7 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 34.8 RYR2 MYH7 DSP
8 familial isolated restrictive cardiomyopathy 34.8 TNNT2 TNNI3
9 cardiomyopathy, familial hypertrophic, 4 34.7 TTN MYBPC3
10 naxos disease 34.5 PKP2 DSP
11 familial isolated dilated cardiomyopathy 34.2 TTN TNNT2 TNNI3 TAZ PLN MYH7
12 arrhythmogenic right ventricular dysplasia, familial, 8 34.1 RYR2 PKP2 DSP
13 intrinsic cardiomyopathy 34.1 TTN TNNT2 TNNI3 RYR2 PKP2 MYH7
14 arrhythmogenic right ventricular dysplasia, familial, 1 34.1 TTN RYR2 DSP
15 arrhythmogenic right ventricular dysplasia, familial, 9 34.0 RYR2 PLN PKP2 DSP
16 glycogen storage disease ii 33.4 PRKAG2 LAMP2 DMD
17 myofibrillar myopathy 33.4 TTN LMNA DMD
18 familial isolated arrhythmogenic ventricular dysplasia, right dominant form 33.4 TTN RYR2 PKP2 LMNA DSP
19 familial isolated arrhythmogenic ventricular dysplasia, left dominant form 33.2 TTN RYR2 PKP2 LMNA DSP
20 familial isolated arrhythmogenic ventricular dysplasia, biventricular form 33.2 TTN RYR2 PKP2 LMNA DSP
21 congenital fiber-type disproportion 33.1 MYH7 LMNA DMD
22 campomelic dysplasia 32.7 TTN MYBPC3 LMNA
23 muscular dystrophy, congenital merosin-deficient, 1a 32.2 LMNA DMD
24 myocarditis 32.0 TNNI3 DSP DMD
25 ventricular fibrillation, paroxysmal familial, 1 31.8 TNNT2 RYR2 DSP
26 cardiac arrest 31.7 TNNT2 RYR2 PLN MYH7 MYBPC3 DSP
27 endocardial fibroelastosis 31.7 TAZ MYH7 ACTN2
28 first-degree atrioventricular block 31.5 MYH7 GJA5
29 wolff-parkinson-white syndrome 31.5 TNNI3 PRKAG2 MYH7 LAMP2
30 catecholaminergic polymorphic ventricular tachycardia 31.4 RYR2 MYBPC3 DSP
31 cardiac conduction defect 31.3 RYR2 PLN MYH7 MYBPC3 LMNA DSP
32 muscular dystrophy, congenital, lmna-related 31.1 TTN LMNA DMD
33 rigid spine muscular dystrophy 1 31.1 TTN MYH7 DMD
34 neuromuscular disease 31.0 TTN LMNA DMD
35 heart disease 31.0 TTN TNNT2 TNNI3 TAZ RYR2 PKP2
36 long qt syndrome 1 30.8 RYR2 PKP2 DSP
37 miyoshi muscular dystrophy 30.8 TTN MYH7 DMD
38 hypertrophic cardiomyopathy 30.8 TTN TNNT2 TNNI3 RYR2 PRKAG2 PLN
39 fabry disease 30.7 TNNI3 PRKAG2 LAMP2 GLA
40 dilated cardiomyopathy 30.6 TTN TNNT2 TNNI3 TAZ RYR2 PRKAG2
41 cardiomyopathy, familial hypertrophic, 1 30.5 TTN TNNT2 TNNI3 MYH7 MYBPC3 ACTC1
42 muscular disease 30.5 TTN TAZ RYR2 MYH7 LMNA LAMP2
43 central core myopathy 30.4 RYR2 MYH7
44 reducing body myopathy 30.3 TTN DMD
45 left ventricular noncompaction 29.9 TTN TNNT2 TAZ RYR2 PKP2 MYH7
46 heart block, congenital 13.0
47 progressive familial heart block, type ib 12.9
48 progressive familial heart block, type ii 12.8
49 cardiomyopathy, infantile histiocytoid 12.7
50 peripartum cardiomyopathy 12.7

Comorbidity relations with Atrial Standstill 1 via Phenotypic Disease Network (PDN):


Heart Disease

Graphical network of the top 20 diseases related to Atrial Standstill 1:



Diseases related to Atrial Standstill 1

Symptoms & Phenotypes for Atrial Standstill 1

Human phenotypes related to Atrial Standstill 1:

32
# Description HPO Frequency HPO Source Accession
1 first degree atrioventricular block 32 HP:0011705
2 endocardial fibroelastosis 32 HP:0001706
3 premature atrial contractions 32 HP:0006699
4 atrial standstill 32 HP:0025478
5 atrial cardiomyopathy 32 HP:0200127

Symptoms via clinical synopsis from OMIM:

57
Lab:
endocardial fibroelastosis

Cardiac:
atrial standstill
atrial cardiomyopathy
first-degree heart block
ectopic supraventricular rhythms
atrial inexcitability

Clinical features from OMIM:

108770

UMLS symptoms related to Atrial Standstill 1:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Atrial Standstill 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased vaccinia virus (VACV) infection GR00249-S 9.96 ACTC1 ACTN2 DMD DSP GJA5 GLA
2 no effect GR00402-S-1 9.92 ACTC1 ACTN2 DMD DSP GJA5 GLA

MGI Mouse Phenotypes related to Atrial Standstill 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.19 ACTC1 DMD DSP GJA5 GLA LAMP2
2 homeostasis/metabolism MP:0005376 9.97 ACTC1 DMD GJA5 GLA LAMP2 LMNA
3 mortality/aging MP:0010768 9.73 ACTC1 DMD DSP GJA5 GLA LAMP2
4 muscle MP:0005369 9.5 ACTC1 DMD DSP GJA5 GLA LAMP2

Drugs & Therapeutics for Atrial Standstill 1

PubMed Health treatment related to Atrial Standstill 1: 63

People who have cardiomyopathy but no signs or symptoms may not need treatment. Sometimes, dilated cardiomyopathy that comes on suddenly may even go away on its own. For other people who have cardiomyopathy, treatment is needed. Treatment depends on the type of cardiomyopathy you have, the severity of your symptoms and complications, and your age and overall health. The main goals of treating cardiomyopathy include: Managing any conditions that cause or contribute to the diseaseControlling signs and symptoms so that you can live as normally as possibleStopping the disease from getting worseReducing complications and the risk of sudden cardiac arrest (SCA) Treatments may include lifestyle changes, medicines, surgery, implanted devices to correct arrhythmias (irregular heartbeats), and/or a nonsurgical procedure.

Drugs for Atrial Standstill 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 509)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verapamil Approved Phase 4 52-53-9 2520
2
Norepinephrine Approved Phase 4 51-41-2 439260
3
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
4
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
7
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
8
Adenosine Approved, Investigational Phase 4 58-61-7 60961
9
Liraglutide Approved Phase 4 204656-20-2 44147092
10
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
11
Doxazosin Approved Phase 4 74191-85-8 3157
12
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
13
Allopurinol Approved Phase 4 315-30-0 2094
14
Deferiprone Approved Phase 4 30652-11-0 2972
15
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
16
Glucagon Approved Phase 4 16941-32-5
17
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
18
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
19
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
20
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
21
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
22
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
23
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
24
Meperidine Approved Phase 4 57-42-1 4058
25
Phenoxybenzamine Approved Phase 4 59-96-1 4768
26
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
27
Propafenone Approved Phase 4 54063-53-5 4932
28
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
29
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
30
Selenious acid Approved, Investigational Phase 4 7783-00-8
31
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
32
Hydralazine Approved Phase 4 86-54-4 3637
33
Probenecid Approved, Investigational Phase 4 57-66-9 4911
34
Ramipril Approved Phase 4 87333-19-5 5362129
35
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
36
Chlorthalidone Approved Phase 4 77-36-1 2732
37
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
38
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
39
Enalaprilat Approved Phase 4 76420-72-9 6917719
40
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
41
Sodium citrate Approved, Investigational Phase 4 68-04-2
42
nivolumab Approved Phase 4 946414-94-4
43
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
44
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
45
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
46
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
47
Empagliflozin Approved Phase 4 864070-44-0
48
tannic acid Approved Phase 4 1401-55-4
49
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
50
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474

Interventional clinical trials:

(show top 50) (show all 1346)
# Name Status NCT ID Phase Drugs
1 Identification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness. Unknown status NCT01904396 Phase 4 Carnitine
2 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Unknown status NCT00879060 Phase 4 spironolactone
3 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
4 A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart Unknown status NCT00326690 Phase 4
5 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
6 Potential Differences Between Levosimendan and Milrinone on Myocardial and Hemodynamic Variables in Patients With Septic Cardiomyopathy. Effects of Norepinephrine on Right Ventricular Function in Patient With Septic Shock. Unknown status NCT02640846 Phase 4 Norepinephrine;Milrinone;Levosimendan
7 A Randomised, Double-Blinded, Placebo-Controlled Trial Using Cardiovascular Magnetic Resonance (CMR) Scanning to Assess Remodelling and Regression of Fibrosis in Cardiomyopathy With Eplerenone Unknown status NCT00401856 Phase 4 Eplerenone;Placebo
8 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
9 A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study Unknown status NCT00541268 Phase 4
10 (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Unknown status NCT02592889 Phase 4
11 Ranolazine Effects on Ischemic Mitral Regurgitation Severity in Patients With Cardiac Resynchronization Therapy Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
12 Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: a Comparison Between Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery Unknown status NCT00388245 Phase 4
13 Carvedilol for the Prevention of Minor Cardiac Damage and Cardiac Function in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4 Carvedilol
14 Novel Strategy For Perioperative Beta-Blocker Therapy - Pilot Study Unknown status NCT02746575 Phase 4 metoprolol
15 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
16 A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease Unknown status NCT00487630 Phase 4 recombinant alpha-galactosidase A
17 Effects of Cardioprotective Therapy, Carvedilol vs Ramipril, in Patients Affected by Duchenne and Becker Muscular Dystrophy. Clinical Significance and Prognostic Value of Cardiac Magnetic Resonance Study. Unknown status NCT00819845 Phase 4 carvedilol;ramipril
18 Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis Unknown status NCT02754518 Phase 4 Entresto
19 Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
20 Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients Unknown status NCT01128101 Phase 4 Spironolactone
21 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
22 A Randomized Trial of the Effects of Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
23 Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation Completed NCT01721967 Phase 4 Ranolazine
24 Ranolazine in Ischemic Cardiomyopathy Patients With Persistent Chest Pain or Dyspnea Despite Conventional Therapy: A Cross-Over Study Completed NCT01345188 Phase 4 Ranexa;Placebo
25 Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial Completed NCT02115581 Phase 4 Coenzyme Q10;Placebo
26 Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
27 A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
28 Effect of Aldosterone on Energy Starvation in Heart Failure Completed NCT00574119 Phase 4 spironolactone
29 ACC - Atrial Contribution to CRT Completed NCT00180323 Phase 4
30 A Multi-center, Randomized, Double, Placebo-controlled, Parallel Group Study of Improving Heart Function and Immunoregulation Effects of Qiliqiangxin Capsule in Patients With Dilated Cardiomyopathy Completed NCT01293903 Phase 4 Qiliqiangxin capsule;Placebo
31 Phase 4. Study of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation. Completed NCT01181414 Phase 4 Beta blocker/digoxine/amiodarone
32 Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart Completed NCT01798992 Phase 4 Carvedilol;Metoprolol succinate;Metoprolol succinate + doxazosin
33 Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study Completed NCT01534026 Phase 4 Aspirin
34 Pilot Study to Assess the Effect of Low Dose Epoetin Beta Administered for Six Month in Patients With Ischemic Heart Failure Subjected to Percutaneous Coronary Intervention (PCI) Completed NCT00568542 Phase 4 erythropoetin beta;placebo
35 Clinical Evaluation on Advanced Resynchronization Completed NCT00658203 Phase 4
36 Protective Effects of Spironolactone Against Anthracycline Induced Cardiomyopathy Completed NCT02053974 Phase 4 Spironolactone
37 Statin Induced Augmentation of Circulating Endothelial Progenitor Cells and Myocardial Viability in Patients With Ischemic and Nonischemic Cardiomyopathy Completed NCT00701220 Phase 4 Atorvastatin Calcium
38 Sympathetic Heart Innervation in Patients With Previous Experience of Transient Stress-induced Cardiomyopathy (Tako-Tsubo): Effects of α-lipoic Acid and L-acetyl Carnitine Therapies. Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
39 Acutely Decompensated Heart Failure in a County Emergency Department: A Double Blind Randomized Controlled Comparison of Nesiritide vs. Placebo Treatment Completed NCT00559338 Phase 4 recombinant B-type, natriuretic peptide;placebo
40 CryoCath Freezor CryoAblation Catheter System (CRYOFACTS) Completed NCT00621621 Phase 4
41 Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Completed NCT01803828 Phase 4 Tadalafil;Placebo
42 Syncope: Pacing or Recording in the Later Years (SPRITELY) Completed NCT01423994 Phase 4
43 Analyse Der Unterschiede Zwischen Aktiv-fixierenden Und Passiv-fixierenden Stimulations-Elektroden Hinsichtlich Implantationsdauer Und Elektrischer Parameter Completed NCT00180557 Phase 4
44 123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging Completed NCT01868841 Phase 4 AdreView
45 Pacing for Cardiomyopathies, a European Study- A Therapy Acceptance Study Completed NCT00180596 Phase 4
46 Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients Completed NCT00477789 Phase 4 allopurinol
47 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
48 Effects of Early Statin Treatment on Symptomatic Heart Failure and Ischemic Events After Acute Myocardial Infarction. The MUSASHI-AMI: A Multicenter Randomized Controlled Trial Completed NCT00128024 Phase 4 lipid-lowering treatment
49 Increased Survival and Reversion of Iron-Induced Cardiac Disease in Patients With Thalassemia Major Receiving Intensive Combined Chelation Therapy Completed NCT00800761 Phase 4 Deferoxamine and Deferiprone;Deferoxamine
50 Diagnosis and Treatment of Acute Coronary Syndrome in the Emergency Department- The Impact of Rapid Bedside cTnl on Outcome. Completed NCT00276432 Phase 4

Search NIH Clinical Center for Atrial Standstill 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Dexrazoxane
Dopamine
Dopamine Hydrochloride
Epinephrine
epinephrine bitartrate
epinephrine hydrochloride
epinephryl borate
Ethanol
Hyoscyamine
Isoprenaline
Isoproterenol
Isoproterenol Hydrochloride
Isoproterenol Sulfate
Racepinephrine Hydrochloride

Cochrane evidence based reviews: heart block

Genetic Tests for Atrial Standstill 1

Genetic tests related to Atrial Standstill 1:

# Genetic test Affiliating Genes
1 Atrial Standstill 1 29 GJA5

Anatomical Context for Atrial Standstill 1

MalaCards organs/tissues related to Atrial Standstill 1:

41
Heart, Testes, Bone, Liver, Endothelial, Bone Marrow, Brain

Publications for Atrial Standstill 1

Articles related to Atrial Standstill 1:

(show top 50) (show all 30340)
# Title Authors PMID Year
1
Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. 38 71
20152563 2010
2
Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. 38 71
20031617 2009
3
Ultrastructural evidence of intercalated disc remodelling in arrhythmogenic right ventricular cardiomyopathy: an electron microscopy investigation on endomyocardial biopsies. 38 71
16774985 2006
4
Familial atrial standstill in association with dilated cardiomyopathy. 38 8
16176547 2005
5
Familial atrial cardiomyopathy with heart block. 38 8
4636548 1972
6
HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). 71
21810866 2011
7
A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. 71
20840742 2010
8
Congenital atrial standstill associated with coinheritance of a novel SCN5A mutation and connexin 40 polymorphisms. 8
16188595 2005
9
A cardiac sodium channel mutation cosegregates with a rare connexin40 genotype in familial atrial standstill. 8
12522116 2003
10
Familial total atrial standstill. 8
1575158 1992
11
Familial atrial dysrhythmia with A-V block. Intracellular microelectrode, clinical electrophysiologic, and morphologic observations. 8
4430108 1974
12
Atrial standstill: a review, and presentation of two new cases of familial and unususal nature with reference to epicardial pacing in one. 8
5347950 1969
13
Involvement of reductive stress in the cardiomyopathy in transgenic mice with cardiac-specific overexpression of heat shock protein 27. 9 38
20439823 2010
14
Cardiomyocyte-targeted overexpression of the coxsackie-adenovirus receptor causes a cardiomyopathy in association with beta-catenin signaling. 9 38
20144615 2010
15
Severe familial left ventricular non-compaction cardiomyopathy due to a novel troponin T (TNNT2) mutation. 9 38
20083571 2010
16
Nesprin-1 mutations in human and murine cardiomyopathy. 9 38
19944109 2010
17
Attenuation of Doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment. 9 38
20101000 2010
18
A common MLP (muscle LIM protein) variant is associated with cardiomyopathy. 9 38
20044516 2010
19
Familial dilated cardiomyopathy secondary to dystrophin splice site mutation. 9 38
20206892 2010
20
Ventricular fibrillation following autologous intramyocardial cell therapy for inherited cardiomyopathy. 9 38
19026577 2010
21
Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. 9 38
19815563 2010
22
Cardiomyopathy: a systematic review of disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations. 9 38
19864899 2010
23
Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. 9 38
20031633 2009
24
Rippling muscle disease and cardiomyopathy associated with a mutation in the CAV3 gene. 9 38
19773168 2009
25
Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. 88
19641226 2009
26
Sarcomere mutations in cardiomyopathy with left ventricular hypertrabeculation. 9 38
20031619 2009
27
Lamin A/C gene mutations in familial cardiomyopathy with advanced atrioventricular block and arrhythmia. 9 38
19638735 2009
28
Association of angiotensin-converting enzyme activity and polymorphism with echocardiographic measures in familial and nonfamilial hypertrophic cardiomyopathy. 9 38
19390744 2009
29
Severe infantile-onset cardiomyopathy associated with a homozygous deletion in desmin. 9 38
19433360 2009
30
Familial amyloid cardiomyopathy due to TTR mutations: an underdiagnosed cause of restrictive cardiomyopathy [corrected]. 9 38
19477408 2009
31
[Anthracycline-induced cardiomyopathy]. 9 38
19423276 2009
32
Unique epidermolytic bullous dermatosis with associated lethal cardiomyopathy related to novel desmoplakin mutations. 9 38
19178614 2009
33
Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. 9 38
19233868 2009
34
Correlation between BNP levels and Doppler echocardiographic parameters of left ventricle filling pressure in patients with Chagasic cardiomyopathy. 9 38
19452608 2009
35
MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. 88
19380620 2009
36
Mutations of plakophilin-2 in Chinese with arrhythmogenic right ventricular dysplasia/cardiomyopathy. 9 38
19427443 2009
37
Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. 9 38
19318653 2009
38
A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. 9 38
19279339 2009
39
Protective effect of geranylgeranylacetone via enhancement of HSPB8 induction in desmin-related cardiomyopathy. 9 38
19399179 2009
40
Stress-induced (Takotsubo) cardiomyopathy: a transient disorder. 9 38
17651835 2009
41
Catecholamine-induced cardiomyopathy. 9 38
19158054 2008
42
Anthracycline-induced cardiomyopathy. 9 38
19020367 2008
43
Dystrophin: from non-ischemic cardiomyopathy to ischemic cardiomyopathy. 9 38
18562127 2008
44
Role of coxsackievirus and adenovirus receptor in the pathogenesis of dilated cardiomyopathy and its influencing factor. 9 38
18959124 2008
45
Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. 9 38
18445662 2008
46
Claudin-5 levels are reduced in human end-stage cardiomyopathy. 9 38
18513742 2008
47
Cardiomyopathy and carnitine deficiency. 9 38
18337137 2008
48
A novel G3337A mitochondrial ND1 mutation related to cardiomyopathy co-segregates with tRNALeu(CUN) A12308G and tRNAThr C15946T mutations. 9 38
18502698 2008
49
Danon disease with typical early-onset cardiomyopathy in a male: focus on a novel LAMP-2 mutation. 9 38
18282207 2008
50
Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? 9 38
18069997 2008

Variations for Atrial Standstill 1

ClinVar genetic disease variations for Atrial Standstill 1:

6 (show top 50) (show all 2991)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 SCN1B NM_001037.5(SCN1B): c.308A> T (p.Asp103Val) single nucleotide variant Pathogenic rs1057519457 19:35524503-35524503 19:35033599-35033599
2 MYBPC3 NM_000256.3(MYBPC3): c.1458-1G> C single nucleotide variant Pathogenic rs397515903 11:47364296-47364296 11:47342745-47342745
3 TTN NM_001267550.2(TTN): c.47961del (p.Gly15988fs) deletion Pathogenic rs1553707780 2:179481655-179481655 2:178616928-178616928
4 TTR NM_000371.3(TTR): c.148G> A (p.Val50Met) single nucleotide variant Pathogenic rs28933979 18:29172937-29172937 18:31592974-31592974
5 TTR NM_000371.3(TTR): c.424G> A (p.Val142Ile) single nucleotide variant Pathogenic rs76992529 18:29178618-29178618 18:31598655-31598655
6 MYBPC3 NM_000256.3(MYBPC3): c.3624del (p.Lys1209fs) deletion Pathogenic rs397516029 11:47354120-47354120 11:47332569-47332569
7 MYBPC3 NM_000256.3(MYBPC3): c.2534_2538del (p.Arg845fs) deletion Pathogenic rs397515973 11:47359006-47359010 11:47337455-47337459
8 MYBPC3 NM_000256.3(MYBPC3): c.2311dup (p.Val771fs) duplication Pathogenic rs397515960 11:47359343-47359343 11:47337792-47337792
9 MYBPC3 NM_000256.3(MYBPC3): c.1895del (p.Met632fs) deletion Pathogenic rs397515934 11:47362691-47362691 11:47341140-47341140
10 PKP2 NM_004572.3(PKP2): c.148_151del (p.Thr50fs) deletion Pathogenic rs397516997 12:33049515-33049518 12:32896581-32896584
11 PLN NM_002667.5(PLN): c.25C> T (p.Arg9Cys) single nucleotide variant Pathogenic rs111033559 6:118880109-118880109 6:118558946-118558946
12 TNNI3 NM_000363.5(TNNI3): c.575G> A (p.Arg192His) single nucleotide variant Pathogenic rs104894729 19:55663260-55663260 19:55151892-55151892
13 TNNT2 NM_000364.4(TNNT2): c.451C> T (p.Arg151Trp) single nucleotide variant Pathogenic rs74315379 1:201333464-201333464 1:201364336-201364336
14 GLA NM_000169.2(GLA): c.640-801G> A single nucleotide variant Pathogenic rs199473684 X:100654735-100654735 X:101399747-101399747
15 PRKAG2 NM_016203.4(PRKAG2): c.905G> A (p.Arg302Gln) single nucleotide variant Pathogenic rs121908987 7:151273498-151273498 7:151576412-151576412
16 PKP2 NM_004572.3(PKP2): c.2146-1G> C single nucleotide variant Pathogenic rs193922674 12:32955491-32955491 12:32802557-32802557
17 DSP NM_004415.4(DSP): c.3474dup (p.Glu1159fs) duplication Pathogenic rs727503000 6:7579897-7579897 6:7579664-7579664
18 PKP2 NM_004572.3(PKP2): c.775G> T (p.Glu259Ter) single nucleotide variant Pathogenic rs1425855043 12:33031039-33031039 12:32878105-32878105
19 MYBPC3 NM_000256.3(MYBPC3): c.551dup (p.Lys185fs) duplication Pathogenic rs397516059 11:47371428-47371428 11:47349877-47349877
20 MYBPC3 NM_000256.3(MYBPC3): c.436dup (p.Thr146fs) duplication Pathogenic rs397516049 11:47371634-47371634 11:47350083-47350083
21 MYH7 NM_000257.4(MYH7): c.788T> C (p.Ile263Thr) single nucleotide variant Pathogenic rs397516269 14:23900635-23900635 14:23431426-23431426
22 MYBPC3 NM_000256.3(MYBPC3): c.3190+5G> A single nucleotide variant Pathogenic rs587782958 11:47355103-47355103 11:47333552-47333552
23 PLN NM_002667.5(PLN): c.37_39AGA[1] (p.Arg14del) short repeat Pathogenic rs397516784 6:118880124-118880126 6:118558961-118558963
24 MYBPC3 NM_000256.3(MYBPC3): c.3372C> A (p.Cys1124Ter) single nucleotide variant Pathogenic rs727504289 11:47354483-47354483 11:47332932-47332932
25 MYBPC3 NM_000256.3(MYBPC3): c.999C> G (p.Tyr333Ter) single nucleotide variant Pathogenic rs367947846 11:47367849-47367849 11:47346298-47346298
26 LAMP2 NM_002294.2(LAMP2): c.584_588dup (p.Val197fs) duplication Pathogenic rs730880492 X:119581848-119581849 X:120447993-120447994
27 MYBPC3 NM_000256.3: c.3315delG deletion Pathogenic
28 LMNA NM_005572.3(LMNA): c.1296_1299GCAC[4] (p.Ser437fs) short repeat Pathogenic rs267607577 1:156106151-156106154 1:156136360-156136363
29 LMNA NM_005572.3(LMNA): c.184C> G (p.Arg62Gly) single nucleotide variant Pathogenic rs56793579 1:156084893-156084893 1:156115102-156115102
30 TTN NM_001267550.2(TTN): c.95134T> C (p.Cys31712Arg) single nucleotide variant Pathogenic rs869320740 2:179410829-179410829 2:178546102-178546102
31 MYH7 NM_000257.4(MYH7): c.1573G> A (p.Glu525Lys) single nucleotide variant Pathogenic rs606231324 14:23897714-23897714 14:23428505-23428505
32 C1QTNF9 ; C1QTNF9B ; MIPEP ; PCOTH ; SACS ; SGCG ; SPATA13 ; TNFRSF19 GRCh37/hg19 13q12.12(chr13: 23519916-24941516)x1 copy number loss Pathogenic 13:23519916-24941516 :0-0
33 ACTN2 NM_001103.3(ACTN2): c.355G> A (p.Ala119Thr) single nucleotide variant Pathogenic rs727502886 1:236882307-236882307 1:236719007-236719007
34 MYBPC3 NM_000256.3(MYBPC3): c.3288del (p.Glu1096fs) deletion Pathogenic rs727503172 11:47354787-47354787 11:47333236-47333236
35 MYBPC3 NM_000256.3(MYBPC3): c.2776_2777CA[2] (p.Thr927fs) short repeat Pathogenic rs727504265 11:47356717-47356718 11:47335166-47335167
36 TNNI3 NM_000363.5(TNNI3): c.509G> A (p.Arg170Gln) single nucleotide variant Pathogenic rs727503503 19:55665438-55665438 19:55154070-55154070
37 MYBPC3 NM_000256.3(MYBPC3): c.1038_1042dup (p.Met348fs) duplication Pathogenic rs730880336 11:47367806-47367810 11:47346255-47346259
38 TNNT2 NM_000364.4(TNNT2): c.835dup (p.Gln279fs) duplication Pathogenic rs730881119 1:201328758-201328758 1:201359630-201359630
39 MYBPC3 NM_000256.3(MYBPC3): c.3327del (p.Met1110fs) deletion Pathogenic rs730880719 11:47354748-47354748 11:47333197-47333197
40 MYBPC3 NM_000256.3(MYBPC3): c.3300_3301CA[1] (p.Thr1101fs) short repeat Pathogenic rs730880671 11:47354772-47354773 11:47333221-47333222
41 MYBPC3 NM_000256.3(MYBPC3): c.3182_3190+4del deletion Pathogenic rs730880718 11:47355104-47355116 11:47333553-47333565
42 MYBPC3 NM_000256.3(MYBPC3): c.3079delGinsAA (p.Asp1027Lysfs) indel Pathogenic rs730880666 11:47355219-47355219 11:47333668-47333668
43 MYBPC3 NM_000256.3(MYBPC3): c.2894_2905+4del deletion Pathogenic rs730880717 11:47356589-47356604 11:47335038-47335053
44 MYBPC3 NM_000256.3(MYBPC3): c.2604del (p.Ser871fs) deletion Pathogenic rs730880655 11:47357561-47357561 11:47336010-47336010
45 MYBPC3 NM_000256.3(MYBPC3): c.3472_3481del (p.Val1158fs) deletion Pathogenic rs730880675 11:47354374-47354383 11:47332823-47332832
46 MYBPC3 NM_000256.3(MYBPC3): c.2543del (p.Ala848fs) deletion Pathogenic rs730880715 11:47359001-47359001 11:47337450-47337450
47 MYBPC3 NM_000256.3(MYBPC3): c.2382del (p.Pro795fs) deletion Pathogenic rs730880714 11:47359272-47359272 11:47337721-47337721
48 MYBPC3 NM_000256.3(MYBPC3): c.1156_1171dup (p.Asp391delinsGlyThrGlyTer) duplication Pathogenic rs730880689 11:47365095-47365110 11:47343544-47343559
49 MYBPC3 NM_000256.3(MYBPC3): c.852-1G> A single nucleotide variant Pathogenic rs368121566 11:47369031-47369031 11:47347480-47347480
50 TTN NM_001267550.2(TTN): c.86387_86391del (p.Arg28796fs) deletion Pathogenic rs794729354 2:179424468-179424472 2:178559741-178559745

UniProtKB/Swiss-Prot genetic disease variations for Atrial Standstill 1:

74
# Symbol AA change Variation ID SNP ID
1 GJA5 p.Pro88Ser VAR_035013 rs121434558
2 GJA5 p.Ala96Ser VAR_035014 rs121434557
3 SCN5A p.Asp1275Asn VAR_026373 rs137854618

Copy number variations for Atrial Standstill 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 39890 10 121400871 121427319 Deletion BAG3 Cardiomyopathy
2 139275 2 178000000 180600000 Loss TTN Cardiomyopathy
3 262125 X 31047265 33267647 Deletion DMD Cardiomyopathy
4 140112 2 191900000 197400000 Loss HSP40 Cardiomyopathy
5 20789 1 154318992 154376502 Deletion LMNA Cardiomyopathy

Expression for Atrial Standstill 1

Search GEO for disease gene expression data for Atrial Standstill 1.

Pathways for Atrial Standstill 1

Pathways related to Atrial Standstill 1 according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.72 TTR TNNT2 TNNI3 RYR2 PLN MYH7
2
Show member pathways
12.59 TTN TNNT2 TNNI3 RYR2 PLN MYBPC3
3
Show member pathways
12.29 RYR2 PLN GJA5 ACTC1
4 12.27 TNNT2 TNNI3 LMNA ACTC1
5
Show member pathways
12.03 RYR2 PKP2 LMNA DSP DMD ACTN2
6 11.65 TNNT2 TNNI3 RYR2 MYH7 ACTC1
7
Show member pathways
11.63 TTN TNNT2 TNNI3 RYR2 PRKAG2 PLN
8 11.36 TNNT2 TNNI3 ACTC1
9 11.36 TTN TNNT2 TNNI3 MYBPC3 DMD ACTN2
10 11.3 RYR2 PLN LMNA GJA5 DSP
11 11.11 GJA5 DSP ACTN2

GO Terms for Atrial Standstill 1

Cellular components related to Atrial Standstill 1 according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 filopodium GO:0030175 9.63 DMD ACTN2 ACTC1
2 intercalated disc GO:0014704 9.58 PKP2 GJA5 DSP
3 myofibril GO:0030016 9.56 TNNT2 TNNI3 MYH7 DMD
4 striated muscle thin filament GO:0005865 9.5 TTN TNNT2 MYBPC3
5 I band GO:0031674 9.49 TTN ACTC1
6 myosin filament GO:0032982 9.48 MYH7 MYBPC3
7 troponin complex GO:0005861 9.43 TNNT2 TNNI3
8 Z disc GO:0030018 9.43 TTN RYR2 MYH7 MYBPC3 DMD ACTN2
9 cardiac Troponin complex GO:1990584 9.37 TNNT2 TNNI3
10 cardiac myofibril GO:0097512 9.33 TNNT2 TNNI3 MYBPC3
11 sarcomere GO:0030017 9.23 TTN TNNT2 TNNI3 RYR2 MYH7 MYBPC3

Biological processes related to Atrial Standstill 1 according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.91 TNNI3 TAZ PKP2 GJA5
2 platelet degranulation GO:0002576 9.84 TTN LAMP2 ACTN2
3 cellular calcium ion homeostasis GO:0006874 9.8 TNNI3 RYR2 PLN
4 regulation of heart rate by cardiac conduction GO:0086091 9.76 PKP2 GJA5 DSP
5 regulation of heart rate GO:0002027 9.73 RYR2 MYH7 DMD
6 skeletal muscle contraction GO:0003009 9.72 TNNT2 TNNI3 MYH7
7 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.71 RYR2 PLN DMD
8 cardiac muscle tissue morphogenesis GO:0055008 9.7 TTN MYBPC3 ACTC1
9 muscle contraction GO:0006936 9.7 TTN TNNT2 TNNI3 TAZ MYH7 MYBPC3
10 cardiac myofibril assembly GO:0055003 9.69 TTN MYBPC3 ACTC1
11 regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0010880 9.67 PLN DMD
12 regulation of cardiac muscle contraction GO:0055117 9.67 RYR2 GJA5
13 ventricular cardiac muscle cell action potential GO:0086005 9.67 RYR2 PKP2 GJA5
14 regulation of the force of heart contraction GO:0002026 9.66 PLN MYH7
15 muscle cell cellular homeostasis GO:0046716 9.65 LAMP2 DMD
16 regulation of muscle contraction GO:0006937 9.65 TNNT2 TNNI3
17 cardiac muscle tissue development GO:0048738 9.65 TAZ PLN
18 striated muscle contraction GO:0006941 9.65 TTN TNNI3 MYH7
19 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.65 TNNT2 TNNI3 PKP2 MYH7 MYBPC3
20 regulation of ryanodine-sensitive calcium-release channel activity GO:0060314 9.64 PLN DMD
21 response to muscle stretch GO:0035994 9.64 RYR2 DMD
22 cardiac muscle fiber development GO:0048739 9.63 TTN MYBPC3
23 skeletal muscle thin filament assembly GO:0030240 9.63 TTN MYBPC3 ACTC1
24 heart contraction GO:0060047 9.62 TNNI3 ACTC1
25 skeletal muscle myosin thick filament assembly GO:0030241 9.62 TTN MYBPC3
26 sarcomere organization GO:0045214 9.62 TTN TNNT2 MYBPC3 ACTN2
27 cardiac muscle hypertrophy GO:0003300 9.61 TTN RYR2
28 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.61 RYR2 PKP2 GJA5
29 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.6 TNNI3 RYR2
30 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.59 PKP2 DSP
31 regulation of AV node cell action potential GO:0098904 9.58 RYR2 GJA5
32 negative regulation of ATPase activity GO:0032780 9.58 TNNT2 TNNI3 PLN
33 regulation of atrial cardiac muscle cell action potential GO:0098910 9.57 RYR2 GJA5
34 muscle filament sliding GO:0030049 9.56 TTN TNNT2 TNNI3 MYH7 MYBPC3 DMD
35 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.54 RYR2 PKP2 DSP
36 cardiac muscle contraction GO:0060048 9.28 TTN TNNT2 TNNI3 TAZ RYR2 MYH7

Molecular functions related to Atrial Standstill 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.93 TTR TTN RYR2 PLN MYBPC3 ACTN2
2 ion channel binding GO:0044325 9.65 RYR2 PKP2 ACTN2
3 actin filament binding GO:0051015 9.55 TTN TNNI3 MYH7 MYBPC3 ACTN2
4 muscle alpha-actinin binding GO:0051371 9.43 TTN MYBPC3
5 myosin binding GO:0017022 9.43 MYBPC3 DMD ACTC1
6 actin binding GO:0003779 9.43 TNNT2 TNNI3 MYH7 MYBPC3 DMD ACTN2
7 titin binding GO:0031432 9.4 MYBPC3 ACTN2
8 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 9.37 PKP2 DSP
9 troponin C binding GO:0030172 9.32 TNNT2 TNNI3
10 structural constituent of muscle GO:0008307 8.92 TTN MYBPC3 DMD ACTN2

Sources for Atrial Standstill 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
66